logo
logo
ZBH stock ticker logo

Zimmer Biomet Holdings, Inc.

NYSE•ZBH
CEO: Mr. Ivan Tornos
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2001-07-25
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Contact Information
345 East Main Street, Warsaw, IN, 46580, United States
574-373-3333
www.zimmerbiomet.com
Market Cap
$17.13B
P/E (TTM)
22.7
27.7
Dividend Yield
1.1%
52W High
$108.29
52W Low
$79.12
52W Range
32%
Rank33Top 25.7%
4.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$2.09B+0.00%
4-Quarter Trend

EPS

$1.22+0.00%
4-Quarter Trend

FCF

$322.90M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Sales Growth 7.2% Net sales increased 7.2% to $8.23B USD in 2025, driven by market growth and Paragon 28 acquisition.
Major 2025 Acquisitions Closed Completed Paragon 28 and Monogram acquisitions, adding significant technology and market share in foot/ankle segments.
Cash Position Strengthened Cash and cash equivalents grew to $591.9M USD by year-end 2025, supported by financing activities.
Volume/Mix Drove Growth Changes in volume and mix of product sales positively affected 2025 sales growth by 6.4 percent.

Risk Factors

Gross Margin Declined Gross margin fell 220 basis points to 61.6% due to inventory charges, tariffs, and acquisition step-up costs.
Earnings Fell Despite Sales Net earnings declined to $705.1M USD, impacted by $170M inventory charges and integration expenses.
Debt Load Increased Total debt increased to $6.93B USD following 2025 acquisitions, raising future servicing requirements.
Sales Force Transformation Risks Converting U.S. sales force from agents to employees presents operational disruptions and potential loss of key personnel.

Outlook

2026 Sales Growth Forecast Expecting 2.5% to 4.5% year-over-year net sales growth in 2026, driven by market and acquisition momentum.
Operating Profit Improvement Expected Operating profit projected to increase in 2026 due to higher net sales and ongoing savings from restructuring plans.
Focus on Technology Integration Continue identifying innovative technologies, potentially through complementary acquisitions or strategic licensing arrangements.
Tax Rate Uncertainty Remains Future effective tax rate remains uncertain due to potential impacts from OECD Pillar 2 framework implementation.

Peer Comparison

Revenue (TTM)

THC stock ticker logoTHC
$21.46B
+4.6%
LH stock ticker logoLH
$14.14B
+7.3%
SNN stock ticker logoSNN
$11.99B
+11.4%

Gross Margin (Latest Quarter)

GMAB stock ticker logoGMAB
92.7%
-0.7pp
INCY stock ticker logoINCY
91.8%
+1.8pp
UTHR stock ticker logoUTHR
82.9%
-1.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BIIB$29.53B21.57.5%22.3%
DXCM$29.08B31.233.8%20.9%
ILMN$24.35B28.934.0%37.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.2%
Moderate Growth
4Q Net Income CAGR
15.9%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:Aug 6, 2026
|
EPS:$1.99
|
Revenue:$2.14B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data